Lipitor approved by health Canada for reducing Heart attack

Pfizer Canada Inc. announced today that
Health Canada has approved the cholesterol-lowering therapy Lipitor(R)
(atorvastatin calcium) to reduce the risk of myocardial infarction in patients
with clinically evident coronary heart disease.
   The approval is based on the wealth of evidence available to date and
further reinforces the previous indication for reduction of cardiovascular
events, such as myocardial infarction and stroke, in patients without
clinically evident coronary heart disease (CHD), but with risk factors for
CHD. This new approval expands the use of Lipitor to patients at risk for
cardiovascular events because of established heart disease such as a prior
heart attack.
   "Lipitor is the world's most extensively studied cholesterol-lowering
medication, and is supported by a large clinical trial program that includes
more than 10 cardiovascular outcomes trials with more than 50,000 patients
across a broad spectrum of risk," said Dr. Bernard Prigent, Vice President and
Medical Director, Pfizer Canada Inc. "Lipitor is the only statin that offers a
unique combination of proven significant cardiovascular event reductions,
impressive average LDL lowering of 39 per cent to 60 per cent, and a
well-established safety profile."

Source:http://www.cnw.ca